Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...

Antihypertensive Drugs: Types of β-Blockers

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

[Interpretation and reflections on the 2025 American Academy of Sleep Medicine clinical practice guideline for the treatment of central sleep apnea in adults].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2026

Same author

[Intermittent hypoxia exposure in the rehabilitation of long COVID patients].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2025

Same author

[Experimental optimization of paraffin sectioning techniques for the eyeball].

[Zhonghua yan ke za zhi] Chinese journal of ophthalmology·2025

Same author

Consensus statement on the multidisciplinary treatment of nasopharyngeal carcinoma with immune checkpoint inhibitors in China.

ESMO open·2025

Same author

[Prognostic factors and survival analysis in rectal cancer patients with poor response to neoadjuvant therapy].

Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery·2025

Same author

[Optimal treatment of obstructive sleep apnea guided by physiological characteristics].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases·2024

Same journal

Great debate: medical treatment of heart failure with reduced ejection fraction will rely on four foundational drugs.

European heart journal·2026

Same journal

The surgical collateralization theory: has the beautiful hypothesis been killed by the ugly facts?

European heart journal·2026

Same journal

Beyond single measurement: additional considerations for high-sensitivity C-reactive protein in cardiovascular risk prediction.

European heart journal·2026

Same journal

Brain mineralocorticoid receptor activation and antagonism in heart failure with preserved ejection fraction: a hypothesis.

European heart journal·2026

Same journal

Myths and misconceptions about high-sensitivity C-reactive protein as a marker of residual inflammatory risk.

European heart journal·2026

Same journal

Vascular Ehlers-Danlos syndrome: should we treat asymptomatic patients?

European heart journal·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 27, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Beta-blockers in cardiac failure

G E Neubauer¹, P Gaudron, M Horn

¹Medizinische Klinik, Julius-Maximilians-Universität, Würzburg, Germany.

European Heart Journal

|August 1, 1994

Summary

This summary is machine-generated.

Beta-blockers offer hemodynamic benefits in chronic heart failure (CHF) by improving exercise capacity. However, their impact on mortality and mechanisms of action require further investigation.

More Related Videos

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Related Experiment Videos

Last Updated: Jun 27, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System

Published on: May 22, 2018

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Area of Science:

Cardiology
Pharmacology

Background:

The role of the sympatho-adrenal system in heart failure (HF) is complex, potentially supporting hemodynamics but increasing cardiac load.
Beta-blocker therapy in HF remains controversial despite evidence of benefits in long-term studies.

Purpose of the Study:

To evaluate the controversial use of beta-blocking agents in patients diagnosed with heart failure.
To explore the hemodynamic and functional effects of beta-blockers in heart failure patients.

Main Methods:

Review of short-term and long-term studies on beta-blocker efficacy in heart failure.
Analysis of hemodynamic parameters including heart rate, left ventricular filling pressure, and exercise capacity.

Main Results:

Long-term studies demonstrate significant hemodynamic benefits and functional improvements in most heart failure patients.
Observed benefits include reduced heart rate, decreased left ventricular filling pressure, and enhanced exercise tolerance.
Mechanisms beyond heart rate reduction remain unclear, and effects on energy metabolism are suggested.

Conclusions:

Beta-blockers provide hemodynamic advantages in heart failure, but their impact on mortality and precise mechanisms require further research.
Identifying specific patient subgroups who benefit most from beta-blocker therapy is crucial.
Further studies are needed to clarify the role of beta-blockers in heart failure prognosis and treatment.